Verrica Pharmaceuticals Inc

VRCA

$5.65

Closing

▲6.20%

1D

▼-22.81%

YTD

Market cap

$239.66M

52 week high

$7.75

52 week low

$2.86

Volume

92,618

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$239.66M

Analysts' Rating

BUY

Price Target (Mean)

12.33333

Total Analysts

6

P/E

Operating Margin

-819.92%

Beta

1.87

Revenue Growth (Annual)

-24.73%

52 week high

$7.75

52 week low

$2.86

Div. Yield

%

EPS Annual Growth

125.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: VP-102, VP-315 and VP-103. The Company’s lead product candidate, VP-102, is a drug-device combination that contains a GMP-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, a contagious and primarily pediatric viral skin disease; external genital warts (EGW), and common warts. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma and non-metastatic Merkel cell carcinoma. The Company is also developing its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot.